Notable companies
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Medtronic plc (NYSE:MDT), Bristol-Myers Squibb Co (NYSE:BMY), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW).
Industry description
The investment seeks results that correspond generally to the price and yield performance, before fees and expenses, of the Indxx Aging Population Thematic Index.
The fund invests more than 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that facilitate the demographic trend of longer average life spans and the aging of the global population, including but not limited to companies involved in biotechnology, medical devices, pharmaceuticals, senior living facilities and specialized health care services.
Market Cap
The average market capitalization across the Global X Aging Population ETF ETF is 50.16B. The market cap for tickers in the group ranges from 35.27M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is FGEN at 35.27M.
High and low price notable news
The average weekly price growth across all stocks in the Global X Aging Population ETF ETF was 16%. For the same ETF, the average monthly price growth was 88%, and the average quarterly price growth was 77%. ATEC experienced the highest price growth at 9%, while ALEC experienced the biggest fall at -29%.
Volume
The average weekly volume growth across all stocks in the Global X Aging Population ETF ETF was -17%. For the same stocks of the ETF, the average monthly volume growth was 14% and the average quarterly volume growth was 7%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 62
P/E Growth Rating: 70
Price Growth Rating: 51
SMR Rating: 65
Profit Risk Rating: 61
Seasonality Score: 30 (-100 ... +100)